BMO Capital Maintains Outperform on Acrivon Therapeutics, Raises Price Target to $25
Portfolio Pulse from Benzinga Newsdesk
BMO Capital analyst Etzer Darout has maintained an Outperform rating on Acrivon Therapeutics (NASDAQ:ACRV) and increased the price target from $18 to $25.
April 26, 2024 | 6:01 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
BMO Capital has reaffirmed its Outperform rating on Acrivon Therapeutics and raised its price target from $18 to $25.
The increase in price target by a reputable analyst like Etzer Darout from BMO Capital is a strong positive signal for Acrivon Therapeutics. It suggests confidence in the company's future performance and potential for growth, likely leading to increased investor interest and potentially a rise in stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100